EyePoint Pharmaceuticals CEO Shows Long-term Commitment Through Family Trust Deal

Rhea-AI Filing Summary

EyePoint Pharmaceuticals President, CEO, and Director Jay S. Duker reported a significant insider transaction on June 23, 2025. The transaction involved the sale of 56,665 shares of common stock at $8.21 per share to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note valued at $465,219.65.

Following the transaction, Duker directly owns 986 shares and indirectly holds 99,165 shares through the Family Trust. The trust is managed by Duker's spouse as trustee and benefits their children. Notably, Duker has disclaimed beneficial ownership of the trust's securities.

Key transaction details:

• Transaction was executed under code 'J' (Other)
• Sale price determined by averaging high/low trading prices on transaction date
• Transaction represents a restructuring of ownership rather than a market sale
• Filing was signed by Ron Honig as Attorney-in-Fact on June 25, 2025

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duker Jay S.

(Last) (First) (Middle)

C/O EYEPOINT PHARMACEUTICALS, INC.

480 PLEASANT STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EyePoint Pharmaceuticals, Inc. [ EYPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2025		J(1)		56,665	D	$8.21	986	D
Common Stock								99,165	I	By Family Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to the Duker Family 2024 Irrevocable Trust, or the Family Trust, in exchange for a promissory note in the principal amount of $465,219.65, representing the fair market value as determined by utilizing the average of the high and low per share trading price on the date of the sale. The shares held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

2. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of EYPT stock did CEO Jay Duker sell on June 23, 2025?

CEO Jay Duker sold 56,665 shares of EYPT common stock on June 23, 2025 at a price of $8.21 per share to the Duker Family 2024 Irrevocable Trust.

What was the total value of EYPT shares transferred by Jay Duker to the Family Trust?

The total value of the transaction was $465,219.65, which was exchanged for a promissory note representing the fair market value based on the average of the high and low trading price on the date of sale.

How many EYPT shares does Jay Duker directly own after the June 23, 2025 transaction?

Following the reported transaction, Jay Duker directly owns 986 shares of EYPT common stock.

What is Jay Duker's indirect ownership of EYPT stock through the Family Trust?

After the transaction, the Duker Family Trust holds 99,165 shares of EYPT stock indirectly. However, Duker disclaims beneficial ownership of these securities, which are held for the benefit of his children with his spouse serving as trustee.

What positions does Jay Duker hold at EYPT as of June 2025?

Jay Duker serves as both the President and CEO of EyePoint Pharmaceuticals, Inc. (EYPT) and is also a Director on the company's board.